We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Johnson & Johnson (J&J) announced that it will acquire the autoimmune-focused biotech company Momenta Pharmaceuticals for $6.5 billion, expanding its holdings in the area of novel treatments for autoimmune diseases. Read More
BioMarin Pharmaceutical announced that the FDA has declined to approve its investigational gene therapy for severe hemophilia A, valoctocogene roxaparvovec, and the agency wants to see two years of follow-up data from a phase 3 study. Read More
Swiss pharma giant Roche is partnering with Regeneron Pharmaceuticals to ramp up production of the New York-based biotech’s COVID-19 antibody cocktail candidate, REGN-COV2. Read More
A federal court in Delaware has ruled that Novartis Pharmaceuticals’ patent for its best-selling multiple sclerosis drug Gilenya (fingolimod) is valid, and HEC Pharm has infringed on it. Read More
Hospitalized COVID-19 patients with pneumonia improved sooner when treated with Vanda Pharmaceuticals’ investigational anti-inflammatory drug tradipitant compared to a placebo, according to interim results from a phase 3 trial. Read More
A second study evaluating the use of the popular heartburn drug famotidine in patients with severe COVID-19 has found that the treatment reduced deaths and the need for intubation. Read More